| Literature DB >> 35743647 |
Charat Thongprayoon1, Caroline C Jadlowiec2, Wisit Kaewput3, Pradeep Vaitla4, Shennen A Mao5, Michael A Mao6, Napat Leeaphorn7, Fawad Qureshi1, Pattharawin Pattharanitima8, Fahad Qureshi9, Prakrati C Acharya10, Pitchaphon Nissaisorakarn11, Matthew Cooper12, Wisit Cheungpasitporn1.
Abstract
BACKGROUND: There have been concerns regarding increased perioperative mortality, length of hospital stay, and rates of graft loss in kidney transplant recipients with functional limitations. The application of machine learning consensus clustering approach may provide a novel understanding of unique phenotypes of functionally limited kidney transplant recipients with distinct outcomes in order to identify strategies to improve outcomes.Entities:
Keywords: clustering; disability; disabled; functional status; kidney transplant; machine learning; transplantation
Year: 2022 PMID: 35743647 PMCID: PMC9225038 DOI: 10.3390/jpm12060859
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Clinical characteristics according to clusters of functionally disabled kidney transplant recipients.
| All | Cluster 1 | Cluster 2 | ||
|---|---|---|---|---|
| Recipient Age (year) | 51.0 ± 13.4 | 52.8 ± 12.7 | 47.2 ± 14.2 | <0.001 |
| Recipient male sex | 1957 (61) | 1422 (64) | 535 (54) | <0.001 |
| Recipient race | <0.001 | |||
|
White | 1521 (48) | 854 (39) | 667 (67) | |
|
Black | 935 (29) | 807 (36) | 128 (13) | |
|
Hispanic | 446 (14) | 302 (14) | 144 (15) | |
|
Other | 303 (9) | 253 (11) | 50 (5) | |
| ABO blood group | 0.02 | |||
|
A | 1176 (37) | 798 (36) | 378 (38) | |
|
B | 432 (13) | 325 (15) | 107 (11) | |
|
AB | 170 (5) | 123 (5) | 47 (5) | |
|
O | 1427 (45) | 970 (44) | 457 (46) | |
| Body mass index (kg/m2) | 28.4 ± 5.8 | 28.7 ± 5.7 | 27.5 ± 5.9 | <0.001 |
| Kidney retransplant | 392 (12) | 89 (4) | 303 (31) | <0.001 |
| Dialysis duration | <0.001 | |||
|
Preemptive | 275 (9) | 124 (6) | 151 (15) | |
|
<1 year | 331 (10) | 162 (7) | 169 (17) | |
|
1–3 years | 1860 (58) | 1500 (68) | 360 (36) | |
|
>3 years | 739 (23) | 430 (19) | 309 (31) | |
| Cause of end-stage kidney disease | <0.001 | |||
|
Diabetes mellitus | 1018 (32) | 809 (36) | 209 (21) | |
|
Hypertension | 643 (20) | 506 (23) | 137 (14) | |
|
Glomerular disease | 585 (18) | 399 (18) | 186 (19) | |
|
PKD | 192 (6.0) | 145 (7) | 47 (5) | |
|
Other | 767 (24) | 357 (16) | 410 (41) | |
| Comorbidity | ||||
|
Diabetes mellitus | 1258 (39) | 958 (43) | 300 (30) | <0.001 |
|
Malignancy | 285 (9) | 174 (8) | 111 (11) | 0.002 |
|
Peripheral vascular disease | 485 (15) | 368 (17) | 117 (12) | <0.001 |
| PRA (%), median (Q25, Q75) | 0 (0, 41) | 0 (0, 17) | 15 (0, 88) | <0.001 |
| Positive HCV serostatus | 158 (5) | 120 (5) | 38 (4) | 0.06 |
| Positive HBs antigen | 68 (2) | 53 (2) | 15 (2) | 0.11 |
| Positive HIV serostatus | 27 (1) | 26 (1) | 1 (0) | 0.002 |
| Functional status | 0.04 | |||
|
10% | 94 (3) | 69 (3) | 25 (2) | |
|
20% | 92 (3) | 54 (3) | 38 (4) | |
|
30% | 122 (4) | 76 (3) | 46 (5) | |
|
40% | 2897 (90) | 2017 (91) | 880 (89) | |
| Working income | 267 (8) | 161 (7) | 106 (11) | 0.001 |
| Public insurance | 2641 (82) | 1902 (86) | 739 (75) | <0.001 |
| US resident | 3192 (99) | 2205 (99) | 987 (99) | 0.23 |
| Undergraduate education or above | 1433 (45) | 965 (43) | 468 (47) | 0.04 |
| Serum albumin (g/dL) | 3.8 ± 0.6 | 3.8 ± 0.6 | 3.7 ± 0.6 | <0.001 |
| Kidney donor status | <0.001 | |||
|
Non-ECD deceased | 2067 (64) | 1587 (72) | 480 (49) | |
|
ECD deceased | 373 (12) | 334 (15) | 39 (4) | |
|
Living | 765 (24) | 295 (13) | 470 (47) | |
| ABO incompatibility | 5 (0) | 0 (0) | 5 (1) | 0.003 |
| Donor age (year) | 39.8 ± 15.1 | 40.3 ± 15.5 | 38.6 ± 14.0 | 0.004 |
| Donor male sex | 1753 (55) | 1265 (57) | 488 (49) | <0.001 |
| Donor race | <0.001 | |||
|
White | 2289 (71) | 1555 (70) | 734 (74) | |
|
Black | 419 (13) | 330 (15) | 89 (9) | |
|
Hispanic | 382 (12) | 258 (12) | 124 (13) | |
|
Other | 115 (4) | 73 (3) | 42 (4) | |
| History of hypertension in donor | 710 (22) | 588 (27) | 122 (12) | <0.001 |
| KDPI | <0.001 | |||
|
Living donor | 765 (24) | 295 (13) | 470 (48) | |
|
KDPI < 85% | 2267 (71) | 1762 (80) | 505 (51) | |
|
KDPI ≥ 85% | 173 (5) | 159 (7) | 14 (1) | |
| HLA mismatch, median (Q25, Q75) | 4 (3, 5) | 5 (4, 5) | 2 (1, 3) | <0.001 |
| Cold ischemia time (hours) | 13.8 ± 9.8 | 15.3 ± 9.5 | 10.3 ± 9.5 | <0.001 |
| Kidney on pump | 1271 (40) | 1059 (48) | 212 (21) | <0.001 |
| Delay graft function | 742 (23) | 616 (28) | 126 (13) | <0.001 |
| Allocation type | <0.001 | |||
|
Local | 2703 (84) | 1937 (87) | 766 (77) | |
|
Regional | 226 (7) | 150 (7) | 76 (8) | |
|
National | 276 (9) | 129 (6) | 147 (15) | |
| EBV status | 0.08 | |||
|
Low risk | 79 (3) | 46 (2) | 33 (3) | |
|
Moderate risk | 2782 (87) | 1926 (87) | 856 (87) | |
|
High risk | 344 (11) | 244 (11) | 100 (10) | |
| CMV status | 0.001 | |||
|
D−/R− | 540 (17) | 342 (15) | 198 (20) | |
|
D−/R+ | 863 (27) | 608 (27) | 255 (26) | |
|
D+/R+ | 1251 (39) | 903 (41) | 348 (35) | |
|
D+/R− | 551 (17) | 363 (16) | 188 (19) | |
| Induction immunosuppression | ||||
|
Thymoglobulin | 1893 (59) | 1306 (59) | 587 (59) | 0.82 |
|
Alemtuzumab | 346 (11) | 230 (10) | 116 (12) | 0.26 |
|
Basiliximab | 631 (20) | 446 (20) | 185 (19) | 0.35 |
|
Other | 82 (3) | 56 (3) | 26 (3) | 0.87 |
|
No induction | 326 (10) | 238 (11) | 88 (9) | 0.11 |
| Maintenance Immunosuppression | ||||
|
Tacrolimus | 2967 (93) | 2050 (93) | 917 (93) | 0.83 |
|
Cyclosporine | 38 (1) | 23 (1) | 15 (2) | 0.25 |
|
Mycophenolate | 2909 (91) | 2012 (91) | 897 (91) | 0.93 |
|
Azathioprine | 25 (1) | 13 (1) | 12 (1) | 0.06 |
|
mTOR inhibitors | 18 (1) | 12 (1) | 6 (1) | 0.82 |
|
Steroid | 1987 (62) | 1372 (62) | 615 (62) | 0.88 |
Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, EBV: Epstein–Barr virus, ECD: Extended criteria donor, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, R: Recipient. SI conversion: Serum albumin: g/dL × 10 = g/L.
Figure 1(A) CDF plot displaying consensus distributions for each k. (B) Delta area plot reflecting the relative changes in the area under the CDF curve. (C) Consensus matrix heat map depicting consensus values on a white to blue color scale of each cluster.
Figure 2(A) The bar plot represents the mean consensus score for different numbers of clusters (K ranges from two to ten). (B) The PAC values assess ambiguously clustered pairs.
Figure 3The standardized differences across two clusters for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: Diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: End stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leukocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: Peripheral vascular disease, R: Recipient.
Post-transplant outcomes according to the clusters of functionally disabled kidney transplant recipients.
| Cluster 1 | Cluster 2 | |
|---|---|---|
| 1-year death-censored graft failure | 4.1% | 2.1% |
| HR for 1-year death-censored graft failure | 1.92 (1.21–3.22) | 1 (ref) |
| 5-year death-censored graft failure | 13.1% | 8.1% |
| HR for 5-year death-censored graft failure | 1.75 (1.28–2.40) | 1 (ref) |
| 1-year death | 6.3% | 3.5% |
| HR for 1-year death | 1.82 (1.26–2.72) | 1 (ref) |
| 5-year death | 20.9% | 16.1% |
| HR for 5-year death | 1.45 (1.15–1.82) | 1 (ref) |
| 1-year acute rejection | 6.7% | 3.8% |
| OR for 1-year acute rejection | 1.80 (1.25–2.60) | 1 (ref) |
Figure 4(A) Death-censored graft failure and (B) patient survival after kidney transplant among two unique clusters of functionally disabled kidney transplant recipients.